On Holdings - On Holdings reported a strong quarterly performance, with earnings per share (EPS) of 54 cents, significantly exceeding the expected 20 cents per share [2] - Revenue surged over 20% year-over-year, surpassing $990 million, driven by strong demand from the Asia-Pacific region where sales more than doubled [2][3] - Gross margins exceeded 65%, benefiting from efficiency gains and favorable currency movements [3] - For fiscal year 2025, On Holdings raised its guidance for net sales growth to at least 34% year-over-year, up from a previous estimate of 31% [4] - Apparel sales increased nearly 87%, indicating strong traction beyond footwear [4] - Analysts are optimistic, with most rating the stock as a buy, and the company plans to adopt a premium pricing strategy without discounts for the holiday season [5][6] Eli Lilly - Citi Group raised its price target for Eli Lilly to $1,500 from $1,250, indicating a potential 50% upside from current levels [8] - The optimism is driven by expectations of FDA approval for a new oral weight loss drug in 2026, which could provide an alternative for patients who prefer pills over injectables [8][9] - Eli Lilly's agreement with the US government to make its obesity and diabetes drugs available through Medicare and Medicaid is seen as a positive catalyst for prescription growth [10] IBM - IBM's shares increased as the company focuses on quantum computing, unveiling a new processor called Quantum Nighthawk [12][14] - The company aims to achieve full quantum computing capabilities by 2029, with the new processor expected to enhance power by over 20% [14] - IBM is collaborating with partners to develop a quantum advantage tracker, which will measure progress in the quantum computing race [14][15] - The stock has risen 5% this week, contributing to a strong performance for the Dow [15][16]